<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04982068</url>
  </required_header>
  <id_info>
    <org_study_id>202-COV-1001</org_study_id>
    <nct_id>NCT04982068</nct_id>
  </id_info>
  <brief_title>Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell)</brief_title>
  <official_title>A Randomized, Double-blinded, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Immunogenicity of the Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy Adults Aged 18 Years and Above</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zerun Biotechnology Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Walvax Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Zerun Biotechnology Co.,Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this double-blind, randomized, controlled study is to assess safety,&#xD;
      reactogenicity, and preliminary immunogenicity of 202-CoV at multiple dose levels,&#xD;
      administered as 2 injections (i.m) at 28 days apart in adult subjects 18 years of age and&#xD;
      above.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of solicited adverse events (AEs) after vaccination</measure>
    <time_frame>7 days after the first or second vaccination</time_frame>
    <description>Percentage of participants with solicited AEs (local, systemic) for 7 days following each primary vaccination (Days 0, 28) by intensity, relevance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of unsolicited AEs after vaccination</measure>
    <time_frame>Frame: Day 0 to Day 56</time_frame>
    <description>Percentage of participants with unsolicited AEs for 28 days following each vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious AEs (SAEs) and adverse events of special interest (AESIs)</measure>
    <time_frame>Day 0 to Month 13</time_frame>
    <description>Percentage of participants with SAEs or AESI for 12month after last dose vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with abnormal markers of hematology, biochemistry, urinalysis and coagulation parameters</measure>
    <time_frame>Day 4 after first or second vaccination</time_frame>
    <description>Safety Laboratory Values (Serum Chemistry, Hematology)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer (GMT) of SARS-CoV-2 neutralising antibodies</measure>
    <time_frame>Day0, Day28, Day42 and Day56</time_frame>
    <description>Neutralizing antibody activity as detected by neutralization assay expressed as GMTs at multiple time points through Day 56</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate (SCR) of SARS-CoV-2 neutralising antibodies</measure>
    <time_frame>Day0, Day28, Day42 and Day56</time_frame>
    <description>Neutralizing antibody activity as detected by neutralization assay expressed as seroconversion rate at multiple time points through Day 56</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer (GMT) of Serum IgG Antibody Levels</measure>
    <time_frame>Day0, Day28, Day42 and Day56</time_frame>
    <description>Serum IgG antibody levels specific for the SARS-CoV-2 S protein antigen as detected by ELISA expressed as GMTs at multiple time points through Day 56</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate (SCR) of Serum IgG Antibody Levels</measure>
    <time_frame>Day0, Day28, Day42 and Day56</time_frame>
    <description>Serum IgG antibody levels specific for the SARS-CoV-2 S protein antigen as detected by ELISA expressed as seroconversion rate at multiple time points through Day 56</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Adult Group 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV low adjuvant dose at Day 0 and Day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult Group 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV low antigen dose at Day 0 and Day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult Group 1c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult healthy subjects (18 to 59 years of age, inclusive) receive 202-CoV standard dose at Day 0 and Day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Adult healthy subjects (18 to 59 years of age, inclusive) receive 2 doses of placebo (saline) at Day 0 and Day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly Group 1d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult healthy subjects (60 years of age and above) receive 202-CoV low adjuvant dose at Day 0 and Day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly Group 1e</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult healthy subjects (60 years of age and above) receive 202-CoV low antigen dose at Day 0 and Day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly Group 1f</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult healthy subjects (60 years of age and above) receive 202-CoV standard dose at Day 0 and Day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Adult healthy subjects (60 years of age and above) receive 2 doses of placebo (saline) at Day 0 and Day 28</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>202-CoV low adjuvant dose</intervention_name>
    <description>standard dose of 202-CoV with low dose CpG / alum adjuvant</description>
    <arm_group_label>Adult Group 1a</arm_group_label>
    <arm_group_label>Elderly Group 1d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>202-CoV low antigen dose</intervention_name>
    <description>low dose 202-CoV with CpG / alum adjuvant</description>
    <arm_group_label>Adult Group 1b</arm_group_label>
    <arm_group_label>Elderly Group 1e</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>202-CoV standard dose</intervention_name>
    <description>standard dose 202-CoV with CpG / alum adjuvant</description>
    <arm_group_label>Adult Group 1c</arm_group_label>
    <arm_group_label>Elderly Group 1f</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline solution</description>
    <arm_group_label>Adult Placebo</arm_group_label>
    <arm_group_label>Elderly Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy individuals aged 18-59 years as well as 60 years and above who can provide&#xD;
             legal identification (males and females are both required).&#xD;
&#xD;
          -  Willing to participate in the study with informed consent prior to screening&#xD;
&#xD;
          -  Negative in SARS-CoV-2 IgG and IgM test at screening.&#xD;
&#xD;
          -  Women of childbearing potential must be using effective method of birth control for 14&#xD;
             days prior to the enrollment of the study vaccine/placebo and must agree to continue&#xD;
             such precautions during the study until 30 days after the second dose of the study&#xD;
             vaccine/placebo.&#xD;
&#xD;
          -  Male subjects must agree to employ acceptable contraception from the day of first dose&#xD;
             of the study vaccine/placebo until 30 days after the second dose of the study&#xD;
             vaccine/placebo.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Confirmed or asymptomatic COVID-19 cases or SARS-CoV-2 infection(had positive in&#xD;
             SARS-CoV-2 nucleic acid test or serological test).&#xD;
&#xD;
          -  Had a history of traveling or residence in domestic area of high and moderate pandemic&#xD;
             risk, overseas or epidemic areas, or had a history of contact with confirmed,&#xD;
             asymptomatic or suspected COVID-19 cases within the past 14 days;&#xD;
&#xD;
          -  History of SARS;&#xD;
&#xD;
          -  Received SARS-CoV-2 vaccines for emergency use or approved SARS-CoV-2 vaccines;&#xD;
&#xD;
          -  Individuals involving a clinical study within 6 months prior to the screening visit;&#xD;
             or planning to participate in another clinical study during study period.&#xD;
&#xD;
          -  Clinical laboratory abnormalities and with clinical significance judged by&#xD;
             investigator&#xD;
&#xD;
          -  Individual's systolic blood pressure ≥ 150mmHg and/or diastolic blood pressure ≥&#xD;
             100mmHg at screening visit&#xD;
&#xD;
          -  Axillary temperature &gt;=37.3℃ prior to vaccination&#xD;
&#xD;
          -  Individuals in other acute diseases, or in the acute phase of chronic diseases within&#xD;
             3 days prior to the signing of the informed consent form.&#xD;
&#xD;
          -  Received immunoglobulin and/or blood product 3 months prior to the first vaccination.&#xD;
&#xD;
          -  Presence of uncontrolled chronic pulmonary, cardiovascular, renal, hepatic,&#xD;
             neurologic, hematologic or metabolic (including diabetes mellitus) disorders, which&#xD;
             would include the potential subject in a high-risk category for SARS-CoV-2 infection&#xD;
             and/or its complications as judged by the investigator..&#xD;
&#xD;
          -  Individuals with a history of severe allergic reaction (throat swelling, difficult in&#xD;
             breath, dyspnea, or shock).&#xD;
&#xD;
          -  Individuals who have a history of severe adverse reaction associated with a vaccine or&#xD;
             severe allergic reaction [e.g., anaphylaxis to any component of the study vaccines (S&#xD;
             protein, Aluminum hydroxide, CpG adjuvant).&#xD;
&#xD;
          -  Any autoimmune or immunodeficiency disease/condition [e.g. human immunodeficiency&#xD;
             virus (HIV) infection, Systemic lupus erythematosus (SLE)]&#xD;
&#xD;
          -  Received immunoglobulin, blood-derived products within 3 months prior to the first&#xD;
             study vaccination.&#xD;
&#xD;
          -  Abnormal coagulation function (such as coagulation factor deficiency, coagulation&#xD;
             disease, platelet abnormality) obvious bruises or coagulopathy.&#xD;
&#xD;
          -  Pregnant women or breastfeeding women.&#xD;
&#xD;
          -  According to the judgment of the investigator, subject has or had any other symptoms,&#xD;
             medical history and other factors that are not suitable for participating in this&#xD;
             clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shengli Xia</last_name>
    <phone>+86 13592610137</phone>
    <email>1792865518@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xiangcheng Center for Disease Control and Prevention</name>
      <address>
        <city>Xuchang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shengli Xia</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

